NLRP3 and early-onset autosomal dominant Alzheimer disease: The NLRP3 inflammasome has been identified as a therapeutic target for the treatment of Alzheimer's disease, and there are many pharmaceutical and academic initiatives underway to develop new small-molecule inhibitors of the NLRP3 inflammasome (e.g., MCC950 and NBCs) (Coll et al., 2015; Baldwin et al., 2017).